Free Trial
NASDAQ:NTHI

Neonc Technologies 5/9/2025 Earnings Report

Neonc Technologies logo
$4.99 +0.85 (+20.53%)
Closing price 04:00 PM Eastern
Extended Trading
$4.86 -0.13 (-2.51%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neonc Technologies EPS Results

Actual EPS
-$2.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Neonc Technologies Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neonc Technologies Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Neonc Technologies' next earnings date is estimated for Friday, May 15, 2026, based on past reporting schedules.

Conference Call Resources

Neonc Technologies Earnings Headlines

$30 stock to buy before Starlink goes public (WATCH NOW!)
A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.tc pixel
NeOnc Raises Capital Through Private Equity Offerings
NeOnc Technologies Holdings Inc NTHI
See More Neonc Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neonc Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neonc Technologies and other key companies, straight to your email.

About Neonc Technologies

Neonc Technologies (NASDAQ:NTHI) develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

View Neonc Technologies Profile